344 related articles for article (PubMed ID: 25396298)
1. Immune evasion in ebolavirus infections.
Audet J; Kobinger GP
Viral Immunol; 2015 Feb; 28(1):10-8. PubMed ID: 25396298
[TBL] [Abstract][Full Text] [Related]
2. Evasion of interferon responses by Ebola and Marburg viruses.
Basler CF; Amarasinghe GK
J Interferon Cytokine Res; 2009 Sep; 29(9):511-20. PubMed ID: 19694547
[TBL] [Abstract][Full Text] [Related]
3. Human transbodies that interfere with the functions of Ebola virus VP35 protein in genome replication and transcription and innate immune antagonism.
Seesuay W; Jittavisutthikul S; Sae-Lim N; Sookrung N; Sakolvaree Y; Chaicumpa W
Emerg Microbes Infect; 2018 Mar; 7(1):41. PubMed ID: 29568066
[TBL] [Abstract][Full Text] [Related]
4. Innate Immune Responses of Bat and Human Cells to Filoviruses: Commonalities and Distinctions.
Kuzmin IV; Schwarz TM; Ilinykh PA; Jordan I; Ksiazek TG; Sachidanandam R; Basler CF; Bukreyev A
J Virol; 2017 Apr; 91(8):. PubMed ID: 28122983
[TBL] [Abstract][Full Text] [Related]
5. Insights into Ebola Virus VP35 and VP24 Interferon Inhibitory Functions and their Initial Exploitation as Drug Targets.
Fanunza E; Frau A; Corona A; Tramontano E
Infect Disord Drug Targets; 2019; 19(4):362-374. PubMed ID: 30468131
[TBL] [Abstract][Full Text] [Related]
6. Camouflage and misdirection: the full-on assault of ebola virus disease.
Misasi J; Sullivan NJ
Cell; 2014 Oct; 159(3):477-86. PubMed ID: 25417101
[TBL] [Abstract][Full Text] [Related]
7. Novel activities by ebolavirus and marburgvirus interferon antagonists revealed using a standardized in vitro reporter system.
Guito JC; Albariño CG; Chakrabarti AK; Towner JS
Virology; 2017 Jan; 501():147-165. PubMed ID: 27930961
[TBL] [Abstract][Full Text] [Related]
8. Transcriptional Analysis of Lymphoid Tissues from Infected Nonhuman Primates Reveals the Basis for Attenuation and Immunogenicity of an Ebola Virus Encoding a Mutant VP35 Protein.
Pinski A; Woolsey C; Jankeel A; Cross R; Basler CF; Geisbert T; Messaoudi I
J Virol; 2021 Feb; 95(6):. PubMed ID: 33408171
[TBL] [Abstract][Full Text] [Related]
9. Different Temporal Effects of Ebola Virus VP35 and VP24 Proteins on Global Gene Expression in Human Dendritic Cells.
Ilinykh PA; Lubaki NM; Widen SG; Renn LA; Theisen TC; Rabin RL; Wood TG; Bukreyev A
J Virol; 2015 Aug; 89(15):7567-83. PubMed ID: 25972536
[TBL] [Abstract][Full Text] [Related]
10. VP24-Karyopherin Alpha Binding Affinities Differ between Ebolavirus Species, Influencing Interferon Inhibition and VP24 Stability.
Schwarz TM; Edwards MR; Diederichs A; Alinger JB; Leung DW; Amarasinghe GK; Basler CF
J Virol; 2017 Feb; 91(4):. PubMed ID: 27974555
[TBL] [Abstract][Full Text] [Related]
11. The Roles of Ebola Virus Soluble Glycoprotein in Replication, Pathogenesis, and Countermeasure Development.
Zhu W; Banadyga L; Emeterio K; Wong G; Qiu X
Viruses; 2019 Oct; 11(11):. PubMed ID: 31683550
[TBL] [Abstract][Full Text] [Related]
12. Filoviral immune evasion mechanisms.
Ramanan P; Shabman RS; Brown CS; Amarasinghe GK; Basler CF; Leung DW
Viruses; 2011 Sep; 3(9):1634-49. PubMed ID: 21994800
[TBL] [Abstract][Full Text] [Related]
13. Host Factors Involved in Ebola Virus Replication.
Rasmussen AL
Curr Top Microbiol Immunol; 2018; 419():113-150. PubMed ID: 28710692
[TBL] [Abstract][Full Text] [Related]
14. Ebolavirus VP35 is a multifunctional virulence factor.
Leung DW; Prins KC; Basler CF; Amarasinghe GK
Virulence; 2010; 1(6):526-31. PubMed ID: 21178490
[TBL] [Abstract][Full Text] [Related]
15. Signaling through RIG-I and type I interferon receptor: Immune activation by Newcastle disease virus in man versus immune evasion by Ebola virus (Review).
Schirrmacher V
Int J Mol Med; 2015 Jul; 36(1):3-10. PubMed ID: 25998621
[TBL] [Abstract][Full Text] [Related]
16. [Research progress on ebola virus glycoprotein].
Ding GY; Wang ZY; Gao L; Jiang BF
Bing Du Xue Bao; 2013 Mar; 29(2):233-7. PubMed ID: 23757858
[TBL] [Abstract][Full Text] [Related]
17. Innate immune evasion by filoviruses.
Basler CF
Virology; 2015 May; 479-480():122-30. PubMed ID: 25843618
[TBL] [Abstract][Full Text] [Related]
18. Ebolavirus protein VP24 interferes with innate immune responses by inhibiting interferon-λ1 gene expression.
He F; Melén K; Maljanen S; Lundberg R; Jiang M; Österlund P; Kakkola L; Julkunen I
Virology; 2017 Sep; 509():23-34. PubMed ID: 28595092
[TBL] [Abstract][Full Text] [Related]
19. Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.
Wang D; Raja NU; Trubey CM; Juompan LY; Luo M; Woraratanadharm J; Deitz SB; Yu H; Swain BM; Moore KM; Pratt WD; Hart MK; Dong JY
J Virol; 2006 Mar; 80(6):2738-46. PubMed ID: 16501083
[TBL] [Abstract][Full Text] [Related]
20. Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins.
Wilson JA; Bray M; Bakken R; Hart MK
Virology; 2001 Aug; 286(2):384-90. PubMed ID: 11485406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
